SAN FRANCISCO, CA--(Marketwire - Mar 30, 2012) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that the company will present data on enzalutamide (formerly MDV3100) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 2, 2012.

Details are as follows:

(Poster #LB-109): MDV3100, an Androgen Receptor Signaling Inhibitor, Inhibits Tumor Growth in Breast Cancer Preclinical Models Regardless of Estrogen Receptor Status

• Monday, April 2, 2012 from 8:00a.m. to noon
  Location: McCormick Place West (Hall F), Poster Section 39

(Poster #2696): Modulation of Intracrine Androgen Signaling in Bone Metastatic Castrate Resistant Prostate Cancer (bmCRPC) by MDV3100

• Monday, April 2, 2012 from 1:00-5:00p.m.
  Location: McCormick Place West (Hall F), Poster Section 27

Medivation also announced that the United States Adopted Names Council has adopted enzalutamide as the generic name for MDV3100, the investigational compound currently in Phase 3 development to treat advanced prostate cancer.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide (formerly MDV3100) in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at [ www.medivation.com ].